{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.0"},{"groupId":"OG001","value":"17.9"},{"groupId":"OG002","value":"21.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"143"}],"units":"Participants"}],"description":"Objective response rate ORR (per RECIST 1.1 as assessed by investigator) is defined as the number (%) of patients with at least 1 visit response of CR or PR.\n\nunconfirmed responses are excluded.","groups":[{"description":"MEDI4736 (Durvalumab) - PD-L1 high","id":"OG000","title":"Monotherapy - PD-L1 High"},{"description":"MEDI4736 (Durvalumab) - PD-L1 low/negative","id":"OG001","title":"Monotherapy - PD-L1 Low/Negative"},{"description":"MEDI4736 (Durvalumab)","id":"OG002","title":"Monotherapy - Total"}],"paramType":"NUMBER","populationDescription":"Durvalumab Cisplatin Ineligible Population include all patients who had received D monotherapy and were not eligible for cisplatin treatment at baseline (per eCRF).","reportingStatus":"POSTED","timeFrame":"Tumour scans performed at baseline then every 8 weeks since randomization until confirmed disease progression. Assessed up to the data cut-off date (01NOV2017, a maximum of 3 years).","title":"Objective Response Rate (ORR) Based on BICR Assessment According to RECIST 1.1 - Responses Are Confirmed - Durvalumab Cisplatin Ineligible Population","type":"SECONDARY","unitOfMeasure":"percentage of participants"}